Study details
Enrolling now
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
Darcy Krueger
NCT IDNCT05104983ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
64
Study length
about 5.7 years
Ages
0.00273790700698851–0.5
Locations
11 sites in AL, CA, CO +7
What this study is about
Researchers are testing sirolimus to prevent or delay seizures in children with Tuberous Sclerosis Complex (TSC). The trial will last for about two years. Participants will be randomly assigned to receive either a placebo or sirolimus.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Placebo
- 2.Take Sirolimus
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IVInjection / IV
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
sirolimus
Drug routes
injection, intravenous
Endpoints
Primary: Safety -- adverse events
Secondary: MRI Biomarkers, Quality of Life Outcomes
Body systems
Neurology